Oxidized Chitosan-Tobramycin (OCS-TOB) Submicro-Fibers for Biomedical Applications

Chitosan (CS) is a biodegradable, biocompatible, and non-toxic natural amino-poly-saccharide with antibacterial ability, owing to its positively charged amino groups. However, the low charge density leads to poor antibacterial efficiency which cannot meet the biomedical application requirements. In...

Full description

Saved in:
Bibliographic Details
Published inPharmaceutics Vol. 14; no. 6; p. 1197
Main Authors Li, Zhen, Mei, Shunqi, Dong, Yajie, She, Fenghua, Li, Chengpeng, Li, Yongzhen, Kong, Lingxue
Format Journal Article
LanguageEnglish
Published Basel MDPI AG 03.06.2022
MDPI
Subjects
Acids
Aqueous solutions
biomedical application
Biomedical materials
centrifugal spinning
chitosan
Contact angle
Cytotoxicity
Fourier transforms
Nanoparticles
NMR
Nuclear magnetic resonance
Polyethylene
Polymers
Scanning electron microscopy
Solvents
Spectrum analysis
submicro-fibers
tobramycin
Viscosity
United States > US
China
Japan
Germany
Online AccessGet full text

Cover

More Information
Summary:Chitosan (CS) is a biodegradable, biocompatible, and non-toxic natural amino-poly-saccharide with antibacterial ability, owing to its positively charged amino groups. However, the low charge density leads to poor antibacterial efficiency which cannot meet the biomedical application requirements. In this study, Tobramycin (TOB) was grafted onto the backbone of oxidized chitosan (OCS) to synthesize oxidized chitosan-tobramycin (OCS-TOB). FTIR, 1H NMR and elemental analysis results demonstrated that OCS-TOB was successfully synthesized. OCS-TOB/PEO composite fibrous materials were produced by a self-made centrifugal spinning machine. In vitro experiments showed that cells proliferated on the submicro-fibrous OCS-TOB/PEO of appropriate concentration, and the antibacterial ability of OCS-TOB was much improved, compared with pristine CS. The results demonstrated that OCS-TOB/PEO nanofibrous materials could potentially be used for biomedical applications.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1999-4923
1999-4923
DOI:10.3390/pharmaceutics14061197